Medical Devices Meet EU HTA: When Regulatory Approval is No Longer the Finish Line

For years, European medical device companies have largely built their evidence strategies around regulatory approval, clinical adoption, and country specific reimbursement. The EU Health Technology Assessment Regulation is beginning to disrupt this sequence. As selected high risk devices enter Joint Clinical Assessments from 2026, manufacturers will increasingly need to answer a question that pharmaceutical companies know well: not simply whether a technology works but how well it works compared with the alternatives that matter to health systems across Europe.

A New Question is Entering the Medtech Boardroom

For a medical device company, securing regulatory approval has traditionally been one of the defining milestones on the path to commercialization in Europe. Demonstrating safety and performance, obtaining a CE mark, developing clinical advocacy, and then navigating reimbursement or procurement market by market formed a relatively familiar progression. This pathway is becoming more complicated.

The EU Health Technology Assessment Regulation, or HTAR, has created a common European framework for assessing the clinical value of health technologies. The regulation became applicable in January 2025, initially focusing on certain medicines. From 2026, selected high risk medical devices and in vitro diagnostics can also undergo EU level Joint Clinical Assessments or JCAs.

Importantly, this does not mean every high risk medical device will automatically undergo a JCA. The regulation covers selected Class IIb and Class III devices, which have undergone the relevant expert panel procedure, and selected Class D diagnostics. Selection can consider factors such as unmet medical need, first-in-class status, impact on health systems, cross border relevance, and the incorporation of artificial intelligence or machine learning.

This distinction matters, as EU HTA is not becoming another universal certification hurdle. Instead, it is creating a new evidence gateway for technologies considered sufficiently important to warrant assessment across Europe. For medtech companies, it may prove more consequential than it initially appears.

From “does it work?” to “what does it improve and compared with what?”

Regulatory assessment and HTA answer different questions. A regulatory process establishes whether a medical device meets the requirements necessary to enter the market. HTA looks beyond market entry. It examines the relative clinical effects of a technology against relevant alternatives so that national health systems can use the evidence in subsequent assessment and reimbursement processes. The JCA does not set a price or make the final reimbursement decision in the European Union; those responsibilities remain at the member state level.

Despite sounding like a procedural distinction, strategically, it is much more. For manufacturers, evidence may increasingly not only need to demonstrate that a device performs safely and effectively but also how its outcomes compare with multiple standards of care across European health systems.

Pharma companies have spent decades building development programs around this reality. Comparative trials, endpoint selection, comparator strategy, health economics and outcomes research, evidence synthesis, and early payer engagement are embedded in many pharmaceutical launch plans.

Medtech has evolved differently. Devices often change rapidly through design iterations. Outcomes can depend on clinician experience, hospital workflow, and learning curves. Randomized controlled trials may be difficult or impractical for certain technologies. The comparator can substantially vary between hospitals and countries. Data available at launch may also be less mature than the evidence traditionally associated with pharmaceutical products. EU HTA, therefore, brings a pharmaceutical style question into a sector whose evidence generation model was not necessarily designed to answer it.

The first implementation signals are already revealing the fault lines

Early research suggests that HTA authorities see significant potential in the new system but also considerable implementation challenges. A 2026 study published in Value in Health interviewed representatives from 11 HTA bodies across 11 EU and European Economic Area countries. Participants broadly supported JCAs as a way to improve evidence quality, share assessment work, and strengthen capabilities, particularly in countries with smaller HTA infrastructures.

Yet readiness was uneven. Some authorities had begun adapting procedures or legislation, while others remained in a more observational position. Respondents identified regulatory uncertainty, resource constraints, timing misalignment between EU and national processes, challenges integrating European assessments into domestic reimbursement pathways, and limited manufacturer preparedness for the evidence demands of JCA as important concerns.

This is arguably the most important early message for the industry. The transition is not simply about learning a new submission template. It is about aligning several systems that have historically developed separately: medical device regulation, clinical evidence generation, EU level comparative assessment, and national reimbursement.

Even mature HTA systems do not evaluate devices in exactly the same way. The same study found considerable variation in how HTA is incorporated into device reimbursement pathways, including differences in whether economic assessment forms part of the process.

The JCA may harmonize part of the clinical assessment, but it is unlikely to eliminate the diversity of national market access environments.

One European assessment can mean many European comparators

The experience with medicines during the first year of EU HTA provides an early warning. One practical challenge has been the number of PICO questions that can emerge during assessment. PICO defines the population, intervention, comparator, and outcomes against which a technology is evaluated. Since treatment pathways and standards of care differ across member states, a European JCA may need to accommodate several nationally relevant comparators and patient populations rather than a single convenient comparison.

For medical devices, this could become particularly demanding. Consider a new interventional technology entering a market where one country primarily uses an established device, another relies more heavily on surgery, and a third has a different patient selection pathway. A clinical program designed around one comparator may leave important evidence gaps elsewhere.

This makes comparator mapping a development issue rather than something to address shortly before reimbursement submission. The commercial implication is straightforward: European market access strategy will need to influence evidence generation earlier.

Clinical, regulatory, and commercial teams can no longer work sequentially, with reimbursement considerations arriving near launch. For technologies likely to fall within the JCA scope, the relevant question may need to be asked several years earlier: what evidence will European health systems eventually need to understand the incremental value of this technology?

The greatest risk may be an evidence strategy built for yesterday’s market

Medical device companies should resist viewing HTA readiness as a documentation exercise. The larger challenge sits upstream.

A manufacturer may successfully complete its regulatory program only to discover that the evidence package cannot readily answer the comparative questions raised through HTA. At that stage, closing the gap can mean new analyses, additional studies, real world evidence generation, or delayed reimbursement discussions.

This makes HTA an R&D and portfolio strategy issue as much as a market access issue. Three changes are likely to become increasingly important.

First, manufacturers will need earlier European evidence planning. Development teams should map likely patient populations, comparators, endpoints, and standards of care across priority European markets before pivotal evidence programs are finalized.

Second, real world evidence will become increasingly strategic. Device performance often evolves after adoption as clinicians move through learning curves, and technologies are used across broader patient populations. Registries and high-quality observational datasets can, therefore, become important components of a lifecycle evidence strategy rather than post launch additions. The HTA framework allows assessments to be updated when important new clinical evidence becomes available.

Third, manufacturers will need to connect regulatory, clinical, and market access decisions. A clinical endpoint that satisfies one stakeholder may not fully answer another stakeholder’s question. A comparator selected because it simplifies a clinical trial may be less useful if it does not reflect relevant European practice.

For larger medtech companies, this may require more integrated evidence functions. For smaller innovators, it creates a more fundamental question: whether sufficient HTA capability exists internally at all.

HTA could also reward better innovation

It would be easy to view the regulation solely as another source of complexity for an industry already navigating MDR and IVDR, potentially leading to a missed opportunity.

A more consistent European approach to comparative clinical assessment could benefit companies whose technologies generate genuinely differentiated outcomes. Smaller HTA systems may gain access to analyses they would struggle to produce independently. Manufacturers may face less duplication of the same clinical evidence requests across countries. Technologies demonstrating meaningful improvements in outcomes may enter national discussions with a stronger common evidence foundation.

The competitive advantage may, therefore, shift. Companies that historically succeeded through strong engineering, regulatory execution, and physician adoption may increasingly need a fourth capability: the ability to prove comparative value at health system level.

This distinction will become particularly important in areas such as AI-enabled devices, novel diagnostics, robotic technologies, implants, and other high cost technologies where adoption can materially influence healthcare budgets and pathways.

Conclusion: The CE mark remains essential, but it is no longer the whole evidence story

EU HTA will neither turn medical devices into pharmaceuticals nor will it eliminate national reimbursement decisions. It introduces a more structured comparative evidence expectation into European medtech market access.

This changes where manufacturers need to start thinking about value. The companies best positioned for the new environment will not be those that begin preparing an HTA dossier shortly before launch. They will be those that anticipate the questions HTA bodies are likely to ask while the clinical evidence strategy is still being designed.

For medtech leaders, the question is becoming less about whether their device can obtain regulatory approval. It is whether the evidence generated on the way to approval will also convincingly and comparatively explain why a European health system should adopt it once it gets there.